Agios on today’s phase 2 data for the pyruvate kinase activator mitapivat in sickle cell disease
The future of gene editing with Intellia’s CEO
Flagship’s small molecule play Empress emerges out of stealth mode
Gene therapy manufacturing at the opening of Ultragenyx’s new plant
Big deals and small molecules with the CEO of Nimbus Therapeutics
BiotechTV U: University of Miami Ph.D. candidates work to build a biotech community in South Florida
OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO
Hopewell Therapeutics’ CEO on the company’s $25M raise and next-gen LNPs
Talking oncology targets (EGFR, FLT3, B7H4 and more) with Cullinan Oncology
Converting infused medicines into subcutaneous injections, including PD-1s, with Halozyme
Discussing the FIREFLY-1 pediatric low-grade glioma data with Day One Bio at #ASCO23
The latest trends in pancreatic cancer research with two experts from MD Anderson
The science and patient experience behind tumor treating fields
Making the case for allo durability at #ASCO23 with Allogene’s CEO
Modality profile: Radiotherapies at #ASCO23 with Dr. Phil Kantoff
Discussing the MIRASOL ovarian cancer data with Immunogen at #ASCO23
Antibody-drug conjugates at #ASCO23 with Seagen’s David Epstein
Biosimilars, toripalimab, and TIGIT with the CEO of Coherus.
The latest on lung cancer advances at #ASCO23 from one of the field’s leading experts
Modality profile: Oncolytic Immunotherapies at #ASCO23
.png){kind=logo}
